Full Text View
Tabular View
No Study Results Posted
Related Studies
Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
This study is currently recruiting participants.
Study NCT00229619   Information provided by National Institutes of Health Clinical Center (CC)
First Received: September 29, 2005   Last Updated: October 8, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Anemia, Aplastic
Red-Cell Aplasia, Pure
Anemia, Diamond-Blackfan
Additional conditions recognized in this trial
Anemia
More general conditions related to this trial
Anemia, Hypoplastic, Congenital
Bone Marrow Diseases
Genetic Diseases, Inborn
Hematologic Diseases
Interventions listed in this trial
Rituximab (Rituxan)
Additional drug interventions recognized in this trial
Rituximab
More general drug interventions related to this trial
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Heart, Lung, and Blood Institute (NHLBI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services